theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Nuclear Medicine

Hematology   

Questions discussed in this category


How do you interpret a Deauville score of 3 on PET when performing mid-treatment assessments in patients with Hodgkin lymphoma?
Are there situations in which a Deauville 3 would cause you to escalate therapy?
2 Answers available
12233


Papers discussed in this category


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-09-20
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Blood, 2016-11-24
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

Lancet, 2012 Apr 04
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Blood, 2018 Aug 30
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.

Related Topics in Nuclear Medicine

  • Radiation Oncology
  • Genitourinary Cancers
  • Medical Oncology
  • Prostate Cancer
  • Hematology
  • Gastrointestinal Cancers
  • Rheumatoid Arthritis
  • Urologic Oncology
  • Urology
  • Imaging

Copyright © 2025 theMednet
All Rights Reserved.